Profund Advisors LLC Makes New Investment in Dianthus Therapeutics, Inc. $DNTH

Profund Advisors LLC bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 21,340 shares of the company’s stock, valued at approximately $879,000.

Other institutional investors also recently bought and sold shares of the company. Patient Square Capital LP purchased a new stake in Dianthus Therapeutics during the third quarter worth $4,919,000. Vanguard Group Inc. boosted its position in Dianthus Therapeutics by 13.6% during the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock worth $64,620,000 after purchasing an additional 196,117 shares in the last quarter. UBS Group AG boosted its position in Dianthus Therapeutics by 342.6% during the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after purchasing an additional 469,547 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Dianthus Therapeutics during the fourth quarter worth $765,000. Finally, Fairmount Funds Management LLC boosted its position in Dianthus Therapeutics by 22.2% during the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after purchasing an additional 600,000 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Ryan Savitz sold 8,224 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the transaction, the executive vice president directly owned 8,224 shares in the company, valued at approximately $738,844.16. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Simrat Randhawa sold 33,830 shares of the stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total value of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,021 shares of company stock valued at $26,564,008 over the last three months. Insiders own 3.02% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on DNTH. Raymond James Financial upgraded Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $63.00 to $123.00 in a research report on Tuesday, March 10th. Jefferies Financial Group set a $98.00 target price on Dianthus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 9th. HC Wainwright boosted their target price on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Finally, Wells Fargo & Company started coverage on Dianthus Therapeutics in a research report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Up 1.0%

Shares of NASDAQ:DNTH opened at $89.63 on Friday. Dianthus Therapeutics, Inc. has a 52-week low of $16.64 and a 52-week high of $96.50. The stock’s fifty day simple moving average is $85.79 and its 200-day simple moving average is $59.99. The company has a market capitalization of $4.90 billion, a P/E ratio of -21.70 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. On average, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.